發(fā)布時間：2018-07-01 12:31

  本文選題：腫瘤 + 歐洲五維健康量表��； 參考：《腫瘤》2017年09期

【摘要】：目的:本研究依托2013—2014年在北京市城市地區(qū)開展的食管癌、胃癌、結直腸癌、肝癌、肺癌和乳腺癌的人群篩查和早診早治現(xiàn)場,采用歐洲五維健康量表EQ-5D-3L和癌癥治療功能評價量表(Functional Assessment of Cancer Therapy,FACT)對癌癥及癌前病變患者的健康相關生活質量進行測量,并分析EQ-5D-3L和FACT針對北京市癌癥人群的信度及效度。方法:采用EQ-5D-3L和FACT同時對1 001例癌癥及癌前病變患者進行測量,對EQ-5D-3L及FACT的結果進行Cronbachα系數(shù)的內部一致性信度檢驗,對FACT采用公因子進行結構效度分析,對EQ-5D-3L和FACT進行對比以實現(xiàn)聚合效度的分析。結果 :對于肺癌、乳腺癌、結直腸癌、食管癌、肝癌和胃癌這6種癌癥,EQ-5D-3L的Cronbachα系數(shù)分別為0.846、0.805、0.877、0.862、0.793和0.844,FACT的Cronbachα系數(shù)分別為0.935、0.916、0.950、0.952、0.915和0.953。在結構效度分析中,FACT累積解釋方差分別為64.28%、65.15%、71.43%、67.21%、64.76%和70.56%。對比FACT,EQ-5D-3L的聚合效度分別為0.592、0.503、0.715、0.672、0.561和0.444,EQ-視覺模擬量表的聚合效度分別為0.553、0.606、0.576、0.579、0.361和0.364。結論 :EQ-5D-3L和FACT應用于北京市癌癥及癌前病變患者的生活質量評估,具有較好的信度。FACT 6種癌癥量表的結構效度較好,肺癌、乳腺癌、結直腸癌、肝癌和食管癌的EQ-5D-3L量表效度也較好,而胃癌及癌前病變的EQ-5D-3L量表效度一般。
[Abstract]:Objective: this study was based on screening and early diagnosis and treatment of esophageal cancer, gastric cancer, colorectal cancer, liver cancer, lung cancer and breast cancer in urban areas of Beijing from 2013 to 2014. EQ-5D-3L and functional Assessment of Cancer Therapeutics were used to measure the health-related quality of life in patients with cancer and precancerous lesions. The reliability and validity of EQ-5D-3L and fact for cancer patients in Beijing were analyzed. Methods: 1 001 patients with cancer and precancerous lesions were measured by EQ-5D-3L and fact. The results of EQ-5D-3L and fact were tested for the internal consistency reliability of Cronbach 偽 coefficients, and the structural validity of the common factors were analyzed. EQ-5 D-3 L and fact were compared to achieve the analysis of polymerization validity. Results: for lung cancer, breast cancer, colorectal cancer, esophageal cancer, liver cancer and gastric cancer, the Cronbach 偽 coefficients of EQ-5D-3L were 0.846 ~ 0.805 ~ (0.877) ~ 0.862 ~ 0.793 and 0.84 ~ (4) FACT, respectively. The Cronbach 偽 coefficients of six kinds of cancer were 0.9350.9160.9500.9520.915 and 0.95353 respectively. In the structural validity analysis, the variance of the cumulative interpretation of facts was 64.285.15 and 71.437.21, 64.76% and 70.5656%, respectively. Compared with facts EQ-5D-3L, the polymerization validity of the EQ-5D-3L was 0.592X 0.503U 0.7150.672U 0.561 and 0.444EQ- visual analogue scale 0.5530.6060.5760.5790.361 and 0.364 respectively. Conclusion the quality of life of patients with cancer and precancerous lesions in Beijing was evaluated by using the weight EQ-5D-3L and fact. The reliability of the six cancer scales was good. The structural validity of the six cancer scales was good, lung cancer, breast cancer, colorectal cancer, lung cancer, breast cancer and colorectal cancer. The validity of EQ-5D-3L scale for liver cancer and esophageal carcinoma was also good, while the validity of EQ-5D-3L scale for gastric cancer and precancerous lesions was moderate.
【作者單位】： 中國醫(yī)學科學院醫(yī)學信息研究所公共衛(wèi)生信息研究室;
【分類號】：R73-31

【相似文獻】

相關期刊論文 前10條

1 周立君;孫韜;陳德嬌;;胃癌前病變患者胃內理化因素的分析[J];山東醫(yī)藥;2008年34期

2 周立君;孫韜;陳德嬌;;胃癌前病變患者胃內理化因素的研究[J];中國煤炭工業(yè)醫(yī)學雜志;2006年03期

3 周立君;孫韜;陳德嬌;;胃癌前病變患者胃內理化因素的研究[J];中國實用內科雜志;2007年S2期

4 溫玲;付建國;王洪慶;;宮頸癌及宮頸癌前病變患者抑郁原因及其影響因素[J];山東醫(yī)藥;2009年41期

5 李隆玉;喬志強;張燕玲;吳云燕;;宮頸癌前病變患者年齡結構的臨床觀察[J];腫瘤防治雜志;2005年24期

6 孫靜華;陳玉;李儀紅;樊明文;侯本祥;孔璐;;胃癌前病變患者口腔細菌多樣性分析[J];北京口腔醫(yī)學;2014年02期

7 謝晶日;王美蓉;李明;;胃靈顆粒對胃癌前病變患者血清生長激素影響的研究[J];中華中醫(yī)藥學刊;2011年02期

8 岳文彬;郭濤;范宗民;王立東;;食管癌及癌前病變患者血清中多個自身抗體檢測的研究[J];河南醫(yī)學研究;2010年02期

9 黃桂玲;錢捷;王少康;蘇明;印虹;孫桂菊;;應用蛋白質芯片檢測食管癌及癌前病變患者血清中的自身抗體[J];腫瘤;2013年12期

10 郭霞;郝軼;吐爾遜帕夏·吾布力卡斯木;哈麗丹·熱依木;納菲沙·卡德爾;武貴臻;阿布力孜·阿布杜拉;;基于蛋白質組學技術篩查維吾爾族婦女宮頸癌前病變患者血漿蛋白預警標志物[J];科技導報;2012年09期

相關會議論文 前2條

1 梁國英;;欣胃顆粒治療胃癌前病變患者臨床觀察[A];第二十五屆全國中西醫(yī)結合消化系統(tǒng)疾病學術會議論文集[C];2013年

2 梁靜;卞美璐;劉霞;歐華;李敏;劉軍;;宮頸癌及癌前病變患者中細胞周期素G1表達及HPV感染的研究[A];中華醫(yī)學會第九次全國婦科腫瘤學術會議論文匯編[C];2006年

相關重要報紙文章 前1條

1 瑚世波邋朱榮緯;子宮癌早診早治項目在鎮(zhèn)安實施[N];商洛日報;2008年

相關博士學位論文 前1條

1 杜芳;食管癌和賁門癌及癌前病變患者血清多種自身抗體微陣列檢測[D];鄭州大學;2006年

，

本文編號：2087797